![Erin Willert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Erin Willert
Keine laufenden Positionen mehr
Karriereverlauf von Erin Willert
Ehemalige bekannte Positionen von Erin Willert
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MOLECULAR TEMPLATES, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Technik-/Wissenschafts-/F&E-Leiter | 09.10.2013 | - |
Ausbildung von Erin Willert
The University of Texas Southwestern Medical Center | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Molecular Templates, Inc. /Old/
![]() Molecular Templates, Inc. /Old/ BiotechnologyHealth Technology Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX. | Health Technology |
- Börse
- Insiders
- Erin Willert
- Erfahrung